CONMED Corporation (CNMD) is a publicly traded Healthcare sector company. As of May 21, 2026, CNMD trades at $36.68 with a market cap of $1.10B and a P/E ratio of 24.16. CNMD moved +1.96% today. Year to date, CNMD is -11.63%; over the trailing twelve months it is -38.15%. Its 52-week range spans $33.21 to $78.00. Analyst consensus is neutral with an average price target of $39.24. Rallies surfaces CNMD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Conmed Q1 EPS Beats Estimates; Refinancing to Add $0.10 Interest Expense: Conmed posted Q1 adjusted EPS of $0.89 on $317M revenue, beating consensus of $0.82 despite a 1.3% sales decline from exiting gastroenterology lines. The company plans bank debt refinancing expected to add at least $0.10 in annual interest expense but maintains full-year EPS guidance of $4.30–4.45.
| Metric | Value |
|---|---|
| Price | $36.68 |
| Market Cap | $1.10B |
| P/E Ratio | 24.16 |
| EPS | $1.52 |
| Dividend Yield | 0.20% |
| 52-Week High | $78.00 |
| 52-Week Low | $33.21 |
| Volume | 70 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.37B |
| Net Income | $47.05M |
| Gross Margin | 54.59% |
4 analysts cover CNMD: 0 strong buy, 0 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $39.24.